Related Experiment Video
Updated: Nov 3, 2025
Noninvasive Sampling of Mucosal Lining Fluid for the Quantification of In Vivo Upper Airway Immune-mediator Levels
Published on: August 7, 2017
Effects of omalizumab in children with asthma: A protocol for systematic review and meta-analysis
1Department of Respiratory, Hunan Children's Hospital, Hunan, China.
Insights
This systematic review will determine if omalizumab is safe and effective for treating pediatric asthma. It aims to provide clear clinical guidance on using this biologic therapy in children with asthma.
Area of Science:
- Pediatric Pulmonology
- Clinical Immunology
Background:
- The efficacy and safety of omalizumab in pediatric asthma patients remain debated.
- Existing evidence lacks a high-quality meta-analysis, necessitating further investigation.
Purpose of the Study:
- To conduct a systematic review and meta-analysis of Level I evidence.
- To ascertain the benefits and safety of omalizumab for children with asthma.
Main Methods:
- Systematic literature review adhering to PRISMA guidelines.
- Searches of PubMed, Scopus, EMBASE, and Cochrane Library (June 2021).
- Meta-analysis using Review Manager software (v 5.3).
Main Results:
- The review will synthesize existing Level I evidence on omalizumab in pediatric asthma.
- Expected to provide compelling evidence and improved clinical guidance.
Conclusions:
- This study will clarify the role of omalizumab in managing pediatric asthma.
- Findings will inform clinical practice regarding omalizumab use in children.
Background:
It is still controversial in the current literature whether omalizumab is beneficial for children with asthma. Given that there is no high-quality meta-analysis to incorporate existing evidence, the purpose of this protocol is to design a systematic review and meta-analysis of the level I evidence to ascertain whether omalizumab is beneficial and safe for children with asthma.
Methods:
The systematic literature review is structured to adhere to Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines. The following search terms will be used in PUBMED, Scopus, EMBASE, and Cochrane Library databases on June, 2021, as the search algorithm: (omalizumab) AND (asthma) AND (children). The primary outcome is the long-term safety and tolerability of omalizumab. The other outcomes include asthma control, quality of life, use of asthma controller medications, and spirometry measurements and emergency room visits due to asthma, and serum trough concentrations of omalizumab, free and total immunoglobulin E measured. Review Manager software (v 5.3; Cochrane Collaboration) will be used for the meta-analysis.
Results:
The review will add to the existing literature by showing compelling evidence and improved guidance in clinic settings.
Registration Number:
10.17605/OSF.IO/G6N3P.
Related Concept Videos
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
01:20Asthma: Pathogenesis and Management
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
01:30Asthma-IV: Diagnostic and Management
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms:
01:26Asthma-II: Pathophysiology and Classification
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
01:30Asthma-IV: Nursing Management
First, in...